Document Detail

Apraclonidine and clonidine: a comparison of efficacy and side effects in normal and ocular hypertensive volunteers.
MedLine Citation:
PMID:  1358852     Owner:  NLM     Status:  MEDLINE    
We performed a prospective, randomized double blind study comparing the cardiovascular and intraocular pressure (IOP) effects of unilateral therapy with clonidine 0.125% and apraclonidine hydrochloride 1.0% in 15 normal and 15 ocular hypertensive volunteers. Baseline values were obtained prior to instillation. One drop of test medication (clonidine, apraclonidine or placebo) was instilled unilaterally, and the post-instillation measurements were taken at 1, 2, 4, 6 and 8 hours. Apraclonidine 1% produced a maximum 31.4% +/- 6.9% (4.83 +/- 1.17 mmHg) decrease in mean IOP in ocular normotensive volunteers and 33.9% +/- 6.9% (10.10 +/- 2.45 mmHg) in ocular hypertensive patients (p < 0.001). These values were 22.1% +/- 6.9% (2.90 +/- 1.94 mmHg) and 22.7% +/- 6.9 (6.80 +/- 2.31 mmHg), respectively in clonidine group (p < 0.001). In apraclonidine group, there were no changes in contralateral IOP, blood pressure or pulse rate. Clonidine produced a significant decrease in contralateral IOP, but this reduction was not statistically significantly different than that of placebo. In clonidine group, there was no change in pulse rate, but a significant decrease in blood pressure. Eyelid retraction, conjunctival blanching and mydriasis were noted in eyes treated with apraclonidine. However there were no statistically and clinically significant changes in pupil size or interpalpebral fissure width with clonidine. This study suggests that apraclonidine appears to be safer and more effective ocular hypotensive agent than clonidine in treatment of glaucoma.
N Yüksel; C Güler; Y Caglar; O Elibol
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  International ophthalmology     Volume:  16     ISSN:  0165-5701     ISO Abbreviation:  Int Ophthalmol     Publication Date:  1992 Sep 
Date Detail:
Created Date:  1992-12-23     Completed Date:  1992-12-23     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7904294     Medline TA:  Int Ophthalmol     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  337-42     Citation Subset:  IM    
Department of Ophthalmology, Cumhuriyet University, School of Medicine, Sivas, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Agonists / adverse effects,  therapeutic use*
Clonidine / adverse effects,  analogs & derivatives*,  therapeutic use*
Double-Blind Method
Intraocular Pressure / drug effects
Middle Aged
Ocular Hypertension / drug therapy*,  physiopathology
Ophthalmic Solutions
Prospective Studies
Reg. No./Substance:
0/Adrenergic beta-Agonists; 0/Ophthalmic Solutions; 4205-90-7/Clonidine; 66711-21-5/apraclonidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Conformational studies of N-Tyr-MIF-1 in aqueous solution by 1H nuclear magnetic resonance spectrosc...
Next Document:  Dopamine, dopaminergic drugs and ocular hypertension.